Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.

Johansson, J; Olsson, A G; Bergstrand, L; Elinder, L S; Nilsson, S; Erikson, U; Mölgaard, J; Holme, I; Walldius, G

Johansson, J; Olsson, A G; Bergstrand, L; Elinder, L S; Nilsson, S; Erikson, U; Mölgaard, J; Holme, I; Walldius, G.

Affiliation

Johansson J; King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden.

Arterioscler Thromb Vasc Biol ; 15(8): 1049-56, 1995 Aug.

Article in En | MEDLINE | ID: mdl-7627695

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Arteriosclerosis / Probucol / Hypercholesterolemia / Cholesterol, HDL Type of study: Clinical_trials / Diagnostic_studies Limits: Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Arterioscler Thromb Vasc Biol Journal subject: ANGIOLOGIA Year: 1995 Document type: Article Affiliation country: Country of publication:

Search on Google

Add to My VHL

XML

PubMed Links